Brokerages Anticipate ESSA Pharma Inc. (NASDAQ:EPIX) to Post -$0.23 EPS

Equities analysts expect ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) to report earnings per share (EPS) of ($0.23) for the current quarter, Zacks reports. Zero analysts have made estimates for ESSA Pharma’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.18). ESSA Pharma reported earnings of ($0.17) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 35.3%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, December 21st.

On average, analysts expect that ESSA Pharma will report full-year earnings of ($0.99) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.89). For the next fiscal year, analysts forecast that the company will report earnings of ($1.13) per share, with EPS estimates ranging from ($1.53) to ($0.71). Zacks’ EPS calculations are an average based on a survey of research analysts that cover ESSA Pharma.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its earnings results on Sunday, August 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.05.

Separately, Oppenheimer reduced their target price on ESSA Pharma from $36.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday, August 16th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, ESSA Pharma has a consensus rating of “Buy” and a consensus target price of $30.25.

In related news, major shareholder Growth N. V. Biotech purchased 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 18th. The stock was bought at an average price of $8.88 per share, for a total transaction of $2,220,000.00. Following the completion of the transaction, the insider now owns 5,015,814 shares in the company, valued at approximately $44,540,428.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.00% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EPIX. RTW Investments LP grew its position in ESSA Pharma by 976.5% in the second quarter. RTW Investments LP now owns 3,053,919 shares of the company’s stock worth $87,250,000 after acquiring an additional 2,770,227 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of ESSA Pharma by 197.8% during the first quarter. Janus Henderson Group PLC now owns 1,516,102 shares of the company’s stock valued at $44,032,000 after buying an additional 1,007,007 shares during the period. Boxer Capital LLC purchased a new position in shares of ESSA Pharma during the first quarter valued at approximately $19,957,000. Bellevue Group AG boosted its position in shares of ESSA Pharma by 34.7% during the second quarter. Bellevue Group AG now owns 2,459,814 shares of the company’s stock valued at $70,277,000 after buying an additional 634,000 shares during the period. Finally, Rock Springs Capital Management LP purchased a new position in shares of ESSA Pharma during the first quarter valued at approximately $14,613,000. Institutional investors own 84.44% of the company’s stock.

Shares of EPIX stock traded down $0.03 during trading hours on Monday, hitting $8.44. The stock had a trading volume of 601 shares, compared to its average volume of 389,858. ESSA Pharma has a one year low of $5.40 and a one year high of $36.00. The stock’s 50-day moving average price is $9.85 and its two-hundred day moving average price is $21.75. The stock has a market capitalization of $341.45 million, a price-to-earnings ratio of -9.01 and a beta of 1.56.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.

Further Reading: Forex

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ESSA Pharma (NASDAQ:EPIX)

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.